Índice

• • ·Ovarian cancer: breaking the silence

    Página :111

     
• • ·Don’t pick the loser: lessons from the GeparQuinto trial

    Página :112-113

    Stephen K Chia

     
• • ·Easing acceleration of head and neck chemoradiotherapy

    Página :113-115

    Missak Haigentz, June Corry, Primoz Strojan, Alfio Ferlito

     
• • ·VEGF Trap for the treatment of malignant ascites

    Página :115-116

    Gerhild Becker, Hubert E Blum

     
• • ·Nasopharyngeal cancer: a promising future

    Página :116-118

    Joseph Wee

     
• • ·Biliary-tract cancer: improving therapy by adding molecularly targeted agents

    Página :118-119

    Lars Henrik Jensen

     
• • ·Prostate cancer therapy: finding the right balance

    Página :119-120

    Fred Saad

     
• • ·PTLD treatment: a step forward, a long way to go

    Página :120-121

    Emili Montserrat

     
• • ·Renaissance of autologous stem cell transplantation for AML?

    Página :121-123

    Felicetto Ferrara

     
• • ·Medical paternalism: who knows best?

    Página :123-124

    Benjamin W Corn

     
• • ·A tale of two tumours and a plea for progress

    Página :124-125

    Rosalie Fisher, Paul Cahalin, Martin Gore, James Larkin

     
• • ·Erratum

    Página :e49

    
• • ·Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine

    Página :e50

    Simona Di Mario, Vittorio Basevi, Silvana Borsari, Sara Balduzzi, Nicola Magrini

     
• • ·Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine – Author’s reply

    Página :e50

    Matti Lehtinen

    
• • ·A STEPP too far for FLEX?

    Página :e51

    Emmanuel Bergot, Christian Creveuil, Gérard Zalcman

     
• • ·A STEPP too far for FLEX? – Authors’ reply

    Página :e51

    Robert Pirker, Stephan Störkel, Anja von Heydebreck, Ilhan Celik, Kenneth J O’Byrne

    
• • ·Persian Gulf states outline regional approach to tackle cancer

    Página :126

    Talha Khan Burki

     
• • ·NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib

    Página :127-128

    Scott Goulden, Frances Sutcliffe, Andrew Stevens

     
• • ·NICE guidance on rituximab for first-line treatment of symptomatic stage III–IV follicular lymphoma in previously untreated patients

    Página :128-130

    Sally Doss, Zoe Garrett, Frances Sutcliffe, Andrew Stevens

     
• • ·Patent expiration offers hope of cheaper cancer drugs

    Página :e52

    DC Sharma

     
• • ·Cancer strategy in the UK: 1 year on

    Página :e52

    Talha Khan Burki

    
• • ·Birth defects in offspring of cancer survivors investigated

    Página :e53

    Talha Khan Burki

     
• • ·Cancer risk in patients with myotonic muscular dystrophy

    Página :e53

    Neil Bennet

    
• • ·Analysis affirms secondary cancer risk with lenalidomide

    Página :e54

    Malini Guha

     
• • ·Mixed messages from US cancer report

    Página :e54

    Bryant Furlow

    
• • ·Qiagen acquires new rights for personalised cancer care

    Página :e55

    David Holmes

     
• • ·Arrests in USA over unapproved stem-cell therapies

    Página :e55

    Bryant Furlow

    
• • ·Nicotine replacement: effective in the long term?

    Página :e56

    Neil Bennet

     
• • ·US EPA carcinogens assessment programme under fire

    Página :e56

    Bryant Furlow

    
• • ·US veterans hospitals lack mammography services

    Página :e57

    Bryant Furlow

    
• • ·Infection risk not increased with alemtuzumab

    Página :e57

    Bryant Furlow

     
• • ·Medikidz explain cancer

    Página :131

    Jill Jouret

     
• • ·The SCAR project: compassion through reality

    Página :132-133

    Lawrence Loh

     
• • ·Trial by media

    Página :133-134

    David Holmes

     
• • ·Voices from the front: February

    Página :134

    David M Mastrianni

    
• • ·Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial

    Página :135-144

    Michael Untch, Sibylle Loibl, Joachim Bischoff, Holger Eidtmann, Manfred Kaufmann, Jens-Uwe Blohmer, Jörn Hilfrich, Dirk Strumberg, Peter A Fasching, Rolf Kreienberg, Hans Tesch, Claus Hanusch, Bernd Gerber, Mahdi Rezai, Christian Jackisch, Jens Huober, Thorsten Kühn, Valentina Nekljudova, Gunter von Minckwitz, for the German Breast Group (GBG), the Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group

    Resumen Resumen Esquema Esquema   
• • ·Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial

    Página :145-153

    Jean Bourhis, Christian Sire, Pierre Graff, Vincent Grégoire, Philippe Maingon, Gilles Calais, Bernard Gery, Laurent Martin, Marc Alfonsi, Patrick Desprez, Thierry Pignon, Etienne Bardet, Michel Rives, Lionel Geoffrois, Nicolas Daly-Schveitzer, Sok Sen, Claude Tuchais, Olivier Dupuis, Stéphane Guerif, Michel Lapeyre, Véronique Favrel, Marc Hamoir, Antoine Lusinchi, Stéphane Temam, Antonella Pinna, Yun Gan Tao, Pierre Blanchard, Anne Aupérin

    Resumen Resumen Esquema Esquema   
• • ·Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study

    Página :154-162

    Walter H Gotlieb, Frederic Amant, Suresh Advani, Chanchal Goswami, Hal Hirte, Diane Provencher, Naresh Somani, S Diane Yamada, Jean-Francois Tamby, Ignace Vergote

    Resumen Resumen Esquema Esquema   
• • ·Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial

    Página :163-171

    Lei Chen, Chao-Su Hu, Xiao-Zhong Chen, Guo-Qing Hu, Zhi-Bin Cheng, Yan Sun, Wei-Xiong Li, Yuan-Yuan Chen, Fang-Yun Xie, Shao-Bo Liang, Yong Chen, Ting-Ting Xu, Bin Li, Guo-Xian Long, Si-Yang Wang, Bao-Min Zheng, Ying Guo, Ying Sun, Yan-Ping Mao, Ling-Long Tang, Yu-Ming Chen, Meng-Zhong Liu, Jun Ma

    Resumen Resumen Esquema Esquema   
• • ·Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial

    Página :172-180

    Nancy Y Lee, Qiang Zhang, David G Pfister, John Kim, Adam S Garden, James Mechalakos, Kenneth Hu, Quynh T Le, A Dimitrios Colevas, Bonnie S Glisson, Anthony TC Chan, K Kian Ang

    Resumen Resumen Esquema Esquema   
• • ·Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study

    Página :181-188

    Jeeyun Lee, Se Hoon Park, Heung-Moon Chang, Jun Suk Kim, Hye Jin Choi, Myung Ah Lee, Joung Soon Chang, Hei Cheul Jeung, Jung Hun Kang, Hyun Woo Lee, Dong Bok Shin, Hye Jin Kang, Jong-Mu Sun, Joon Oh Park, Young Suk Park, Won Ki Kang, Ho Yeong Lim

    Resumen Resumen Esquema Esquema  
• • ·Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials

    Página :189-195

    Anthony V D’Amico, Ming-Hui Chen, Mario de Castro, Marian Loffredo, David S Lamb, Allison Steigler, Philip W Kantoff, James W Denham

    Resumen Resumen Esquema Esquema   
• • ·Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial

    Página :196-206

    Ralf Trappe, Stephan Oertel, Veronique Leblond, Peter Mollee, Monica Sender, Petra Reinke, Ruth Neuhaus, Hans Lehmkuhl, Heinz August Horst, Gilles Salles, Franck Morschhauser, Arnaud Jaccard, Thierry Lamy, Malte Leithäuser, Heiner Zimmermann, Ioannis Anagnostopoulos, Martine Raphael, Hanno Riess, Sylvain Choquet, for the German PTLD Study Group, the European PTLD Network

    Resumen Resumen Esquema Esquema   
• • ·Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial

    Página :207-214

    Markus Pfirrmann, Gerhard Ehninger, Christian Thiede, Martin Bornhäuser, Michael Kramer, Christoph Röllig, Joerg Hasford, Markus Schaich, for the Study Alliance Leukaemia (SAL) ‡

    Resumen Resumen Esquema Esquema   
• • ·Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC

    Página :e58

    Augusto Caraceni, Geoffrey Hanks, Stein Kaasa, Michael I Bennett, Cinzia Brunelli, Nathan Cherny, Ola Dale, Franco De Conno, Marie Fallon, Magdi Hanna, Dagny Faksvåg Haugen, Gitte Juhl, Samuel King, Pål Klepstad, Eivor A Laugsand, Marco Maltoni, Sebastiano Mercadante, Maria Nabal, Alessandra Pigni, Lukas Radbruch, Colette Reid, Per Sjogren, Patrick C Stone, Davide Tassinari, Giovambattista Zeppetella, for the European Palliative Care Research Collaborative (EPCRC), on behalf of the European Association for Palliative Care (EAPC)

    Resumen Resumen Esquema Esquema  
• • ·Chordoma: current concepts, management, and future directions

    Página :e69

    Brian P Walcott, Brian V Nahed, Ahmed Mohyeldin, Jean-Valery Coumans, Kristopher T Kahle, Manuel J Ferreira

    Resumen Resumen Esquema Esquema  
• • ·Consensus-based standards for best supportive care in clinical trials in advanced cancer

    Página :e77

    S Yousuf Zafar, David C Currow, Nathan Cherny, Florian Strasser, Robin Fowler, Amy P Abernethy

    Resumen Resumen Esquema Esquema   
• • ·The developing cancer stem-cell model: clinical challenges and opportunities

    Página :e83

    Louis Vermeulen, Felipe de Sousa e Melo, Dick J Richel, Jan Paul Medema

    Resumen Resumen Esquema Esquema